ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO584

Associations of Bone-Related Markers and Cognitive Function in Hemodialysis Patients

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Wu, Ping-Hsun, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
  • Lin, Yi-Ting, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
  • Tsai, Jer-Chia, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
  • Kuo, Mei-Chuan, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Background

Patients undergoing hemodialysis (HD) have a higher risk of cognitive impairment than the general population but limited data elucidated the biomarkers on this. We evaluate the association of bone turnover markers on cognitive function among 251 prevalent HD enrollees in a cross-sectional study.

Methods

251 HD patients (median age=57.8; 55% men) without a prior stroke or dementia diagnosis were enrolled. Circulating levels of 8 bone markers (receptor activator of nuclear factor kappa-Β ligand [RANKL], dickkopf-related protein 1 [DKK1], fibroblast growth factor 23 [FGF23], leptin, osteocalcin [OC], Osteopontin [OPN], osteoprotegerin [OPG], sclerostin [SOST]) were analyzed by a multiplex immunobead assay (Millipore, St Charles, MO, US). The association between bone-related markers and cognitive function test (Mini-Mental State Examination [MMSE], Montreal Cognitive Assessment [MoCA], and Cognitive Abilities Screening Instrument [CASI]) were investigated in a linear regression model.

Results

Among 8 bone-related markers, RANKL was the only bone markers found associated with cognitive function (MMSE, MoCA, and CASI test) in HD patients (Figure). In stepwise multiple linear regression analysis, the positive association remained statistically significant in MoCA (β=1.14, 95% CI 0.17 to 2.11) and CASI (β=3.06, 95% CI 0.24 to 5.88). Short-term memory (β=0.52, 95% CI 0.01 to 1.02), mental manipulation (β=0.51, 95% CI 0.05 to 0.96), and abstract thinking (β=0.57, 95% CI 0.06 to 1.09) were significant domain in CASI score.

Conclusion

Serum RANKL levels were found potential associated with higher cognitive function test in HD patients. Further large scale and prospective studies are needed to confirm our findings.

Funding

  • Government Support - Non-U.S.